The Second Xiangya Hospital of Central South University, Changsha (China)
1
presentation
0
follower
4
more
presentations
in this session
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)